Background. Metabolic syndrome is associated with high cardiovascular morbidity and mortality and its increasing prevalence is becoming one of the major health problems. Atherothrombotic process is accelerated in the metabolic syndrome and this is attributed to metabolic abnormalities, hypofibrinolysis due to increased plasma PAI-1 levels, and inflammation. Proinflammatory cytokines, particularly tumour necrosis factor-a may have an important role in PAI-1 overexpresion in the adipose tissue. PAI-1 might be involved in the etiopathogenesis of obesity and insulin resistance. Conclusions. To understand a complex interplay between metabolic syndrome, PAi-1 and atherosclerosis further studies are needed.

Rights

URN

URN:NBN:SI:DOC-K0TJLOQE

COBISSID

19576537

Added

10.04.2014

Metadata

Citation

APA:

Mavri, Alenka (2005). Povezava med metabolnim sindromom, inhibitorjem aktivatorja plazminogena (PAI-1) in aterosklerozo. Zdravniški vestnik, volume 74, issue 6, str. 375-379. URN:NBN:SI:DOC-K0TJLOQE from http://www.dlib.si

MLA:

Mavri, Alenka. "Povezava med metabolnim sindromom, inhibitorjem aktivatorja plazminogena (PAI-1) in aterosklerozo." Zdravniški vestnik volume 74. issue 6 (2005) str. 375-379.
<http://www.dlib.si/?URN=URN:NBN:SI:DOC-K0TJLOQE>

Zdravniški vestnik
1992-
(Assembly record)

Povezava med metabolnim sindromom, inhibitorjem aktivatorja plazminogena (PAI-1) in aterosklerozoMetabolic syndrome, plasminogen activator inhibitor (PAI-1) and atherosclerosis

Povezava med metabolnim sindromom, inhibitorjem aktivatorja plazminogena (PAI-1) in aterosklerozo
Metabolic syndrome, plasminogen activator inhibitor (PAI-1) and atherosclerosis